HOME > REGULATORY
REGULATORY
- Commentary: Spiking Drug Prices Behind Harvoni Pricing Spat at Chuikyo
August 28, 2015
- PFSB to Monitor Drug Companies’ Promotional Activities at 20 Selected Medical Facilities
August 28, 2015
- PFSB to Request Budget of 10.7 Billion Yen in FY2016 to Improve Environments for Development of Innovative Drugs, Quality of Generics
August 28, 2015
- Health Service Bureau Seeks 469.1 Billion Yen in FY2016 Budget, 120.2 Billion Yen for Intractable Diseases
August 28, 2015
- Health Policy Bureau Seeks 193.6 Billion Yen in FY2016 Budget, 6.6 Billion Yen for Clinical Research Promotion
August 28, 2015
- FPMAJ Wants Continuation of Innovation Premium, No Market Price-Based Price Revision in 2017: Chuikyo Hearings
August 27, 2015
- Chuikyo’s HTA Panel Issues Interim Report, Appraisal Results to Be Used to Re-Price Selected Listed Drugs
August 27, 2015
- Development Projects, Regulatory Filings Increasing Thanks to Innovation Premium: PhRMA, EFPIA
August 27, 2015
- MHLW Seeks 30.7 Trillion Yen in FY2016 Budget, 104.3 Billion for Drug, Healthcare Initiatives
August 27, 2015
- Chuikyo Reps Trade Barbs over Pricing of Harvoni, Listing OK'ed by a Whisker
August 27, 2015
- Chuikyo OKs Listing of Harvoni, Peak Sales Put at 119 Billion Yen in 2nd Year
August 26, 2015
- 4 Pharma Groups Welcome MHLW’s “Comprehensive Strategy”
August 25, 2015
- MHLW OKs New Indications for Remicade, Other Products
August 25, 2015
- MHLW Reveals Outline of “Comprehensive Strategy” for Pharma Sector
August 25, 2015
- Drug Pricing Tomorrow: MHLW Councilor Takeda Says NHI Drug Prices Should Mirror Evaluation of Individual Firms
August 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for August 10 - August 23
August 24, 2015
- PMDA Reviewing Opdivo for Risk of Myasthenia Gravis
August 24, 2015
- Novartis’s Equa-Metformin Combination Drug Added to PAFSC 1st Committee’s Review List for Aug. 28
August 24, 2015
- MHLW Designates Carfilzomib as Orphan Drug
August 21, 2015
- Lawmakers Discuss Cost-Effectiveness of Measures to Prevent Cervical Cancer
August 21, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…